

SWEDISH AMERICAN LIFE SCIENCE SUMMIT 2021

PRESENTING COMPANIES & RISING STARS


anocca


BIOARCTIC


BICO


Dvysr®


orexo


SYMCEL


RhoVac


ultimovacs


Amniotics


EPI ENDO
PHARMACEUTICALS


atrogi


iaterion


ILYA
PHARMA


SIGRID
THERAPEUTICS


MOBIUS
BIOMEDICAL


Vironova BioAnalytics


Vironova


SAGA DIAGNOSTICS

SWEDISH AMERICAN LIFE SCIENCE SUMMIT 2021

PRESENTING COMPANIES

RISING STARS

SWEDISH AMERICAN LIFE SCIENCE SUMMIT 2021

PRESENTING COMPANIES



TRANSFORMATIVE T-CELL RECEPTOR IMMUNOTHERAPIES TO TREAT CANCER AND OTHER SERIOUS DISEASES

Anocca's highly scalable and validated platform allows development of novel T-cell therapies across a vast target space in numerous therapy areas.

www.anocca.com

SALSS CONTACT

Reagan Jarvis
CEO

reagan.jarvis@anocca.com
+46 709 10 47 81

Anocca AB
Forskargatan 20C
Building 229
151 36 Södertälje
Sweden

anocca

Annoca AB | Private Company

Anocca is a privately held biotechnology company founded in 2014. Anocca has established an engineered human cell-based discovery, validation and clinical development platform for deciphering T-cell immunity and delivering next generation T-cell therapies.

Based in modern facilities near Stockholm, Sweden, Anocca has built up a talented team of over 70 scientists. The company has raised over USD 100 million since inception.

OUR PRODUCTS & SERVICES

Anocca is deploying its highly scalable precision analysis technologies to develop transformative T-cell receptor (TCR) immunotherapies to treat cancer and other serious diseases. The company has pioneered a proprietary analytical cell biology platform that enables a deep understanding of disease specific T cell biology to deliver highly targeted cell-based therapies. The company's innovative approach to deciphering T cell immunity can reach an unprecedented number of druggable targets in oncology and other therapeutic areas, such as infectious diseases and autoimmune disorders. Anocca has fully integrated R&D capabilities, with a range of scalable, automated analytics platforms leveraging extensive libraries of engineered cells, complemented by clinical manufacturing and process development facilities, all underpinned by custom IT infrastructure developed in-house. The company's platform has generated a broad pipeline of high value assets which it expects to progress to the clinic in a combination of wholly-owned and partnered programmes.

WHAT MAKES US UNIQUE

To unlock the untapped full potential of TCR immunotherapies, Anocca uses a sophisticated industrialised approach. Its end-to-end proprietary platforms, driven by the analysis of functional cell biology, are deployed to identify immunogenic disease targets and clinically actionable TCRs with a breadth, depth and precision unique in the industry.

WHY YOU SHOULD MEET US

We are looking to engage in discussions for:

1. Collaborative partnerships focusing on discovery and development of novel TCRs based on selected disease targets.
2. Partnering of proprietary preclinical shared tumour antigen and shared driver mutation oncology assets, including novel TCRs targeting KRAS mutant antigens.
3. Investment in future financings to drive growth through fueling Anocca's manufacturing and clinical development capabilities.

KEY TEAM

Reagan Jarvis, PhD
CEO & Scientific Founder

- 8 years experience in Anocca leadership
- Formerly researcher at the DKFZ German Cancer Center

Jacob Michlewicz
CFO

- 20+ years of experience, with McKinsey & Co and managerial positions in pharma, biotech and medtech across EU and US

Hugh Salter, PhD
CSO

- 20+ years of experience in pharma R&D
- Head, AstraZeneca Translational Science Centre, KI, CSO Moderna Sweden

Mark Farmery, PhD
VP, Business Development

- Senior level biopharma business developer
- Formerly VP, Business Development, Abliva, Karolinska Institutet Innovations and Karo Bio, Business Development Director AstraZeneca

SWEDISH AMERICAN LIFE SCIENCE SUMMIT 2021

BICO

BICO Group AB | Nasdaq Stockholm: BICO

LEADING THE BIOCONVERGENCE REVOLUTION

By combining the synergistic power of biology, engineering and computer science, BICO is extending the boundaries of the possible to give people better, healthier lives and creating the future of health.

We see a future where robotics, artificial intelligence, advanced genomics and bioprinting come together to fundamentally shift the global healthcare industry.

Founded in 2016, BICO (formerly CELLINK) is the world's leading bioconvergence company. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better. The Group's products are trusted by more than 2,000 laboratories, including the top 20 pharmaceutical companies, are used in more than 65 countries, than 9,000 publications.

OUR PRODUCTS & SERVICES

BICO Group consists of 13 subsidiary companies with 37 offices and 1000+ employees worldwide, providing technology, products and services.

Bioprinting
- CellInk
- Mattek
- Visikol
- Nanoscribe
- Advanced BioMatrix

Biosciences
- Dispendix
- Cytena
- Cytena BPS
- Echo

Bioautomation
- Scienion
- Cellenion
- Ginolis

Together we enable researchers and scientists within bioprinting, multiomics, cell line development and diagnostics to grow cells in 3D environments, conduct high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries.

WHAT MAKES US UNIQUE

Bioconvergence emphasizes the synergy between engineering, technology and computerized systems. Bioconvergence is based on the understanding that biology and tech, the two pillars of biotechnology, aren't as hard to reconcile as they appear. By integrating biology research with engineering expertise and by recognizing that these are two sides to the same coin, BICO, as the leading bioconvergence company, is pushing the industry forward and helping to create the future of medicine.

WHY YOU SHOULD MEET US

We aim to strengthen our position as the leading player on the global market for bioconvergence, which is expected to be in excess of USD 200 billion.

KEY TEAM

Erik Gatenholm, MBA
CEO, Co-founder
- CEO since 2016
- Documented success in biotechnology entrepreneurship with more than 13 years of entrepreneurial experience.
- Forbes 30 Under 30, MIT Review 35 Under 35, and Entrepreneur of the year 2020

Hector Martinez, PhD
CTO, co-founder
- Mechanical and biomedical engineer
- Doctorate in Cartilage Tissue Engineering from Chalmers University of Technology
- 8 years' experience in biomaterials, tissue engineering and 3D bioprinting technologies

Gusten Danielsson, MSc
CFO, co-founder
- Founder of Escape House and Matvänner
- Previously CEO of Handels Capital Management

SWEDISH AMERICAN LIFE SCIENCE SUMMIT 2021

SALSS CONTACT

Isabelle Ljunggren
Head of Communications

il@bico.com
+46 708 30 08 90

BICO Group AB
Arvid Wallgrens Backe 20
413 46 Gothenburg
Sweden

www.bico.com

BIOARCTIC

BioArctic AB | Nasdaq Stockholm: BIOA B

INNOVATIVE TREATMENTS HELPING PATIENTS WITH DISEASES IN THE CNS

Exciting portfolio of differentiated first-generation disease modifying agents in Alzheimer's and Parkinson's disease

BioArctic AB is a Swedish research-based biopharma company focusing on disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, where there is a high unmet medical need.

The company was founded in 2003 based on innovative research from Uppsala University, Sweden.

OUR PRODUCTS & SERVICES

BioArctic has developed several unique and selective antibodies with the potential to slow the progress of Alzheimer's disease.

The most advanced drug candidate, lecanemab (BAN2401) is currently being evaluated in two Phase 3 studies: Clarity AD for early Alzheimer's disease and AHEAD 3-45 for preclinical (asymptomatic) Alzheimer's disease. Lecanemab previously showed convincing results in a large Phase 2b study in patients with early Alzheimer's disease. The development of lecanemab against Alzheimer's disease is being financed and pursued by BioArctic's partner Eisai.

In the Parkinson's disease treatment area, BioArctic has been collaborating with AbbVie since 2016. In 2018, AbbVie acquired a license to develop and commercialize BioArctic's portfolio of antibodies against alpha-synuclein for Parkinson's disease and other potential indications.

WHAT MAKES US UNIQUE

BioArctic has cutting-edge scientific competence, experience in developing drugs from idea to market and a solid cash position of close to SEK 1 billion. Collaborations with universities are of great importance to the company together with the strategically important global partners in the AD and PD projects. Through long-term collaboration agreements with global pharma companies, BioArctic has demonstrated high skill level and great ability to deliver innovative pharmaceutical projects.

WHY YOU SHOULD MEET US

The project portfolio consists of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and out-licensing potential.

We are interested to meet investors and potential licensing partners for our innovative programmes.

KEY TEAM

Gunilla Osswald, PhD
President & CEO

- 35+ years experience in drug development
- Formerly VP, Neurodegeneration Disease Modification, Astra Zeneca

Lars Lannfelt, MD, PhD
Founder, SVP

- Senior Professor at Uppsala University
- Member of the Royal Swedish Academy of Sciences

Tomas Odergren, MD, PhD
VP, CMO

- 20+ years pharma industry experience in leading positions in clinical development at Astra Zeneca and H Lundbeck

Johanna Fälting, PhD
VP, Head of Research

- 20+ years in neuroscience/ pharmacology, drug research, translational science and development in the global pharma and biotech industry

SWEDISH AMERICAN LIFE SCIENCE SUMMIT 2021

SALSS CONTACT

Oskar Bosson
VP Communications & Investor Relations

oskar.bosson@bioarctic.se
+46 704 10 71 80

BioArctic AB
Warfvinges väg 35
112 51 Stockholm
Sweden

www.bioarctic.se

Dvysr®

DEVYSER DIAGNOSTICS AB | Public Company

SPECIALIZED IN THE DEVELOPMENT, MANUFACTURE AND SALE OF MARKET-LEADING GENETIC DIAGNOSTIC KITS

Building a fast growing global diagnostic company for complex DNA testing within hereditary diseases, oncology and post-transplantation monitoring.

Founded in 2004, Devyser is a specialized provider of advanced genetic test kits combined with software adapted to the leading DNA sequencing platforms. We develop and manufacture products in Sweden, and sell to 45+ countries from our four international offices as well as distributors. Our focus is to provide solutions that are easy to implement, maintain, and use resulting in substantial time and cost savings for our clinical diagnostic lab customers. We are focused on three areas; hereditary diseases, oncology and post-transplantation monitoring.

OUR PRODUCTS & SERVICES

We sell diagnostic kits for complex DNA testing within hereditary diseases, oncology and transplantation. Our products are used to guide targeted cancer therapies, to enable rapid prenatal diagnostics, as well as in post transplant follow-up.

Devyser sells a range of standardized genetic diagnostics covering:

- Transplantation
- Thalassemias
- Oncology
- Fetal RHD screening NIPT
- Hereditary
- Cystic fibrosis
- Cardiovascular
- Male infertility
- Rapid aneuploidy analysis

WHAT MAKES US UNIQUE

For patients, wait time and result clarity is absolutely critical. We are relentlessly focused on simplifying and streamlining complex testing processes to improve throughput and eliminate tedious protocols - in one case reducing a test the time taken to perform a test from weeks to only hours.

The results are tests that are simpler, faster and easier to use in routine diagnostics laboratories and the reason why you can find our products in use in diagnostic laboratories in more than 45 countries worldwide.

WHY YOU SHOULD MEET US

We have demonstrated stable and profitable growth, exceeding 35% in average, for several years now and are looking to expand our global marketing and sales. We are interested to meet investors, partners, distributors and customers interested to share our successful development journey.

KEY TEAM

Fredrik Alpsten
CEO

- Life-science executive with broad experience within publicly traded, private and VC-financed companies, as CEO, CFO and other exec positions
- Experience of multiple IPOs on Nasdaq Stockholm

Ulf Klangby
Deputy CEO and founder

- Fil. Lic in Tumor Biology from Karolinska Institute
- Founded the company in 2004

Sabina Berlin
CFO

- Former CFO of IRRAS, listed on Nasdaq Stockholm main list
- 10+ years experience in financial control

SWEDISH AMERICAN LIFE SCIENCE SUMMIT 2021

www.devyser.com

SALSS CONTACT

Fredrik Alpsten
CEO

fredrik.alpsten@devyser.com
+46 706 67 31 06

Devyser Diagnostics AB
Instrumentvägen 19 Sweden
126 53 Hägersten
Sweden

Orexo

OREXO AB | STO:ORX | OTCQX:ORXOY(ADR)

DEVELOPING AND COMMERCIALIZING IMPROVED PHARMACEUTICALS AND CLINICALLY PROVEN DIGITAL THERAPIES

Building on our competences and where we believe we can make greatest impact, we are focusing on improving the lives for patients suffering from mental illness and substance use disorders

Orexo develops improved pharmaceuticals and clinically proven digital therapies addressing unmet needs within the growing space of mental illness and substance use disorders. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercializes its lead product ZUBSOLV® for treatment of opioid use disorder. The company is headquartered in Uppsala, Sweden, where research and development activities are performed.

OUR PRODUCTS & SERVICES

Pharmaceuticals:

- **ZUBSOLV®** – a medication assisted treatment for opioid use disorder
- **OX124** – an overdose rescue medication designed to reverse the effect of overdoses caused by the most powerful synthetic opioids. Under development and expected to be launched on the US market in 2023.

Clinically proven digital therapies:

- **vorvida®** – for alcohol misuse, including alcohol use disorder, a standalone treatment or complementary to pharmaceuticals
- **deprexis®** – for depression, astandalone treatment or as a complement to pharmaceuticals.
- **modia™** - for opioid dependence and for use with medication assisted treatments

Orexo´s digital therapies are in-licenced from, or developed with, one of the world's leading developers – GAIA AG. All therapies are rooted in cognitive behavioural therapy techniques and are highly individualized as the technology platform is based on AI technology.

WHAT MAKES US UNIQUE

- In-depth understanding of patient needs within mental illness and substance use disorders
- Comprehensive experience of developing new pharmaceuticals and the requirements to get them approved
- Pioneer in adding evidence-based digital therapies to improve treatment outcomes
- Strong cash contribution from a profitable US Pharma segment (EBIT 2020, ~$40 m)

WHY YOU SHOULD MEET US

Our main strategic focus is to leverage our commercial excellence and strong market access network in the US, by continuing to add synergistic products to the commercial platform. Commercial portfolio expansion can be made through acquisition or by in-licensing. Orexo is also seeking partners for out-licensing of products outside the US and is offering a full service platform for DTx companies.

KEY TEAM

Nikolaj Sørensen
President & CEO

- 25+ years of experience in CEO and senior leading positions in the pharma and management consultancy industry

Robert A. DeLuca
President, Orexo US, Inc.

- 20+ years of relevant experience mainly from senior leading positions in the US digital health industry

Dennis Urbaniak
EVP Digital Therapeutics

- 30+ years of experience in building up or managing commercial pharmaceutical businesses

Michael Sumner
Chief Medical Officer

- 25+ years from similar positions has led to in-depth knowledge to ensure patients, physicians and regulatory agencies are provided with information for safe and appropriate use of Orexo´s products

SALSS CONTACT

Nikolaj Sørensen
President & CEO

nikolaj.sorensen@orexo.com
+46 187 80 88 00

Orexo AB
Box 303
751 05 Uppsala
Sweden

www.orexo.com

SWEDISH AMERICAN LIFE SCIENCE SUMMIT 2021

RhoVac

TARGETING METASTASES TO PREVENT CANCER RECURRENCE AND PROGRESSION AFTER PRIMARY TUMOUR THERAPY

RhoVac is currently in Phase IIb clinical development for prostate cancer patients with BioChemical Recurrence (BCR), with a unique mechanism of action that targets a universal epitope of potential metastatic cancer cells.

RhoVac, founded in 2007, is an immunotherapy company listed on the Spotlight stock market in Sweden, with a 100%-owned subsidiary in Denmark. RhoVac's core technology is based around the fundamental discovery that RhoC protein is over-expressed in all potential metastatic cells, and that this protein is essential to the ability of metastatic cells to migrate and infiltrate tissues outside of the primary tumour. The company's lead candidate, RV001, uses a RhoC fraction as an antigen, activating T-cells to recognise cells with RhoC overexpression, and eliminating these cells.

OUR PRODUCTS & SERVICES

RhoVac's RV001 lead therapeutic in development is currently in phase IIb clinical trials for prostate cancer, following a successful phase I trial that demonstrated safety and tolerability, and that 86% of patients attained the desired, stable RhoC specific immune response. A recent 3-year follow-up of this study demonstrated excellent results in terms of PSA remission and maintained RhoC-specific immunity.

This study will be completed during first half of 2022, and is designed to produce statistically significant results on RV001 efficacy in preventing disease progression in prostate cancer after surgery or radiation therapy to the primary tumour. In November 2020, RhoVac received US FDA "Fast Track Designation" for the development of RV001 in prostate cancer.

WHAT MAKES US UNIQUE

RhoC is what gives the metastatic cells their crucial ability to migrate out of the primary tumour and spread. Only metastatic cells over-express RhoC, so RV001 specifically targets cells with metastatic potential. Our treatment paradigm is preventive: instead of targeting established metastatic tumours, the treatment targets the deadly seed of undetectable metastatic cells often left behind after primary tumour surgery or radiation therapy, which can eventually cause cancer recurrence.

The RhoC based cancer vaccine concept was suggested as "ideal" by the American National Cancer Institute back in 2009, and since then it has been demonstrated to work pre-clinically for many types of cancer, offering hope of a completely tissue agnostic cancer vaccine concept for prevention of metastases.

WHY YOU SHOULD MEET US

The RhoVac concept has huge potential. Upon positive phase IIb results (H1 2022), RhoVac will be looking for a licensing partner, or an acquirer, capable of taking RV001 through phase III and to a global launch.

KEY TEAM

Anders Månsson
CEO

- 25 years of experience in pharmaceuticals.
- Senior executive positions in multinational companies both in Sweden and abroad

Henrik Stage, MSc
CFO

- 25 years' experience in leading biotechnology and finance sectors positions industry
- Successful exit of Santaris Pharma, to Roche for $450M

Steffen Wad Jørgensen, PhD
Chief Development Officer

- Experience in project coordination of both early and late clinical development
- Formerly with Lundbeck within Corporate Project Management
- PhD, Immunology and Clinical Chemistry

SWEDISH AMERICAN LIFE SCIENCE SUMMIT 2021

www.rhovac.com

SALSS CONTACT

Anders Månsson
CEO

ama@rhovac.com
+46 708 60 47 38

RhoVac AB
Scheeletorget 1
223 81 Lund
Sweden



LEADING A PARADIGM SHIFT IN RAPID DIAGNOSIS OF INFECTIONS USING METABOLIC MEASUREMENTS

Symcel uses microcalorimetry of unprecedented sensitivity to detect metabolic signatures that enable order-of-magnitude faster phenotypic diagnosis of infection and prediction of antibiotic in-vivo effects.

Our aim is to replace the current gold standard of conventional microbiological culture for identification and AMR determination.

www.symcel.com

SALSS CONTACT

Jesper Ericsson
CEO

jesper.ericsson@symcel.com
+46 739 80 56 86

Symcel AB
Tomtebodavägen 6
171 65 Solna
Sweden

SYMCEL

Symcel AB | Private Company

Founded in 2004, Symcel is a medtech company applying cell metabolic signatures for ultra-rapid pathogen characterisation and diagnosis of infections, which are expected to be the leading cause of death in 20 years. We are on-market with calScreener™, the first microcalorimeter designed specifically for cell biology, which directly measures metabolic activity with unprecedented sensitivity. Our solution addresses the entire chain of detection, ID and drug testing, with high-value applications in healthcare, from research to drug development to clinical practice.

OUR PRODUCTS & SERVICES

Every metabolic reaction produces energy. Our flagship solution, calScreener™ is an in-vitro culturing system that measures metabolic heat output in real time with exquisite sensitivity, enabling the consecutive detection and ID of microorganisms in clinical specimens. It enables phenotypic response measurements that reveal how cells and bacteria live or die in response to antibiotics or other drugs under testing. We have demonstrated 95% accurate identification within 5 hours of a positive signal, more than 10x faster than conventional culturing.

At our clinical partner site at the University of Alabama (UAB) in the US, calScreener has demonstrated clinical feasibility in over 250 patients with prosthetic joint infections (PJIs). Detection time has been reduced 10-fold, from an average of 2.5 days to just 5 hours, enabling same day results.

WHAT MAKES US UNIQUE

Our patent-protected technology is unique in providing real time, morphology-independent, quantitative insight into the metabolic status of a cell or tissue sample.
This is fundamental to success in drug development and diagnostics. This will be a game-changer for:

- Making drug development more effective, by bridging the gap between in-vitro and in-vivo testing.
- Developing the worlds fastest diagnosis of live bacteria and pathogens in implant and tissue related infections, with an initial focus on orthopedic infections.

WHY YOU SHOULD MEET US

We have already achieved validation and have secured one of Sweden´s largest H202 grants in Dec 2017 of $4.5M for testing of antibiotics against multi-resistant bacteria in sepsis patients. We are interested to meet partners and investor who want to change the future of severe infections with a rapid and robust diagnostic solution.

KEY TEAM

Jesper Ericsson, PhD
CEO

- Business driver with experience in commercializing science-based companies

Magnus Jansson, PhD
CTO

- Extensive experience in drug discovery and development

Niklas Jakobsson, MSc
COO

- Extensive career within QA/QC, regulatory affairs and product development of medtech products

Humberto Salgado, MBA
S&M Director

- Extensive experience in international sales

Wilhelm Paulander, PhD
Director of Application and Business Development

- Extensive experience from in-vitro diagnostic development and infectious disease areas

SWEDISH AMERICAN LIFE SCIENCE SUMMIT 2021

ACTIVATING THE IMMUNE SYSTEM TO FIGHT CANCERS WITH NEXT-GEN UNIVERSAL CANCER VACCINES

Our lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase.

Ultimovacs' strategy is to clinically demonstrate UV1's impact in many cancer types and in combination with other immunotherapies.



www.ultimovacs.com

SALSS CONTACT

Carlos de Sousa
CEO

carlos.desousa@ultimovacs.com
+47 908 92 507

Ultimovacs ASA
Ullernchausséen 64
0379 Oslo
Norway

Ultimovacs ASA | OSLO Stock Exchange: ULTI

Ultimovacs is a Euronext Oslo listed biotech company developing its lead immuno-therapy program UV1 in a number of phase II clinical development trials, thereby advancing its next-generation proprietary peptide-based universal cancer vaccine program. The aim of UV1 is to generate a specific immune response against cancer cells, regardless of type. Multiple phase I studies in different cancer indications, have confirmed safety and tolerability, as well as efficacy, and have demonstrated favorable survival outcomes. The company has since initiated four phase II combination studies.

OUR PRODUCTS & SERVICES

Ultimovacs' lead universal cancer vaccine candidate UV1 targets human telomerase (hTERT), present in over 85% of cancers in all stages of tumor growth. By directing the immune system to hTERT antigens, UV1 drives CD4 helper T cells to the tumor to activate an immune system cascade and increase anti-tumor responses. With a broad Phase II program, Ultimovacs aims to clinically demonstrate UV1's impact in multiple cancer types in combination with other immunotherapies. Ultimovacs' second technology approach, based on the proprietary Tetanus-Epitope-Targeting (TET) platform, combines tumor-specific peptides and adjuvant in the same molecule and the Company entered phase I studies in 2021.

WHAT MAKES US UNIQUE

Checkpoint inhibitor monotherapies show limited responsiveness and are of limited duration. UV1 generates a strong immune response combined with reduced tumor defense, and an anti-tumor response that broadens over time.

UV1 has the potential to be:

- Applicable to treat a wide range of cancers by targeting telomerase, expressed in 85-90% of all tumors
- Combined with a broad range of cancer therapies and is under evaluation in combination with ipilimumab, pembrolizumab, nivolumab, durvalumab and olaparib.
- An off-the-shelf peptide vaccine, that can be produced via standard synthesis, with properties allowing for a simple intra-dermal administration procedure and with no need for complex infrastructure at the clinic.

WHY YOU SHOULD MEET US

Ultimovacs is interested in discussing UV1 with potential partners, both using UV1 in combination trials with other drug modalities or in case of program partnering interest. The Company is currently funded to H1 2023.

KEY TEAM

Carlos de Sousa
CEO

- 30+ years of indsutry experience as MD and leadership positions at international pharma companies

Hans Vassgård Eid
CFO

- 20+ years' experience within business development, VC & PE investments

Ton Berkien
CBO

- 15+ years experience in healthcare business development, both pharmaceuticals and biotech

Audun Tornes
CTO

- 15+ years' experience within pharma industry, >10 patents in diagnostics and cancer therapy.

Jens Bjørheim
CMO

- MD PhD with clinical oncology experience and scientific merits within immunology and cancer genetics

SWEDISH AMERICAN LIFE SCIENCE SUMMIT 2021

Vironova

Vironova AB | Private Company

MAKING THE INVISIBLE VISIBLE TODAY

Vironova is a Swedish biotechnology company providing comprehensive hardware, software and services for the analysis of nanoparticles.

We are revolutionizing transmission electron microscopy for sub-visible particle analysis.

www.vironova.com

SALSS CONTACT

Raheleh Nassaji
Director, Business Development

raheleh.nassaji@vironova.com
+46 73 545 22 66

Vironova AB
Gävlegatan 22
113 30 Stockholm
Sweden

Founded in Stockholm in 2005, Vironova is a Swedish biotechnology company providing comprehensive hardware, software and services for the analysis of nanoparticles. We support our partners through the whole value chain, from initial sample preparation to imaging and final analytical result. Our dedicated team provide insightful and actionable data, empowering clients to make better-informed decisions, to create value and ensure safety for patients worldwide.

OUR PRODUCTS & SERVICES

Vironova provides fast and cost-effective electron microscopy services enabled by our own software and hardware. Our services are performed in the world's only GMP-certified TEM laboratory, creating reliable and traceable results. We are the only company with a full-service value chain offer from start to finish.

MiniTEM™ is a compact and agile transmission electron microscope system designed for automated nanoparticle characterization. High-resolution images reveal particle morphologies that are transformed into accurate metrics. It provides pharmaceutical organizations worldwide with an advanced semi-automated microscope which helps them to save time and hence frees up their time to do other tasks.

WHAT MAKES US UNIQUE

Transmission electron microscopy (TEM) has previously been an expensive and complex practice to use in gene therapy, vaccine and drug development. At Vironova, we focus on supporting our partners by lowering technical thresholds, minimizing analytical complexity and provide business critical insights for the development of biopharmaceuticals targeting previously untreatable conditions. By combining deep industry expertise and data-driven insights, we help clients solve real needs by making the subvisible accessible.

Vironova is in pole position to capture value and growth opportunities in this ever-evolving landscape. TEM paired with our intelligent software and experience, is the leading method capable of producing a reliable and accurate analysis for the development of novel therapies.

WHY YOU SHOULD MEET US

Vironova is the preferred partner for life science companies, setting the golden standard for safe and effective therapy development. With over 200 established customer relationships, a strong acquisition pipeline of new clients and deep inroads with the global research community, we build trust in the therapies of tomorrow by making the invisible visible today.

KEY TEAM

Mohammed Homman
CEO

- Founder of Vironova AB and Vironova Medical AB
- 10+ years research at KI
- MSc, Chemistry and BSc, Biology from Uppsala University

Ida-Maria Sintorn, MSc, PhD
CTO

- Vironova since 2007
- Associate professor in computerized image processing at Uppsala University

Maria Homman, PhD
COO

- Previously Member of the Board (2006-2011) and Chairman of the Board (2006-2008).
- Manager within R&D at AkzoNobel

Raheleh Nassaji, MSc
Dir, Business Development

- 13+ years int'l experience with Pzifer
- MSc in Business Administration from SSE & MSc in Biomedical Science from KI

SWEDISH AMERICAN LIFE SCIENCE SUMMIT 2021

SWEDISH AMERICAN LIFE SCIENCE SUMMIT 2021

RISING STARS

Amniotics

Amniotics AB | Public NASDAQ First North: AMNI

PIONEERING NEONATAL QUALITY AND TISSUE-SPECIFIC STEM CELL THERAPIES

Amniotics has established an end-to-end and fully integrated internal manufacturing chain from collection through finished product to maximize value.



Amniotics is a biopharma company pioneering the harvesting and propagation of tissue specific neonatal quality mesenchymal stem cells (MSC) from amniotic fluid with unique properties for applications in regenerative medicine. Amniotics also has its own in-house operational GMP facility to produce advanced therapy medicinal products and is now moving into clinical trials with the lead drug candidate, PulmoStem™.

Amniotics is listed at Nasdaq First North Growth Market in Stockholm.

OUR PRODUCTS & SERVICES

We have a pipeline based on our know-how and IP around a novel way to harvest and manufacture tissue-specific off-the-shelf stem cells derived from amniotic fluid. Our first lead drug candidate PulmoStem™ is expected to enter phase I/II in 1H 2022.

We are preparing the first clinical trial in COVID-19-induced ARDS. The study will provide safety data and may provide early indications of the anti-inflammatory and/or anti-fibrotic components effects in patients using biomarkers.

WHAT MAKES US UNIQUE

Our technology is based around amniotic fluid-derived MSC. Pre-natal infants deposit MSC into the amniotic fluid from tissue in contact with the fluid. This source, which is ethically derived and otherwise considered a medical waste product, can produce an array of different tissue-specific stem cell therapies targeting lung, skin, kidney, and brain diseases, which are believed to potentially lead to better therapeutic effects.

WHY YOU SHOULD MEET US

We have recently raised SEK60 million through a listing on Nasdaq First North Growth Market to advance our lead candidate Pulmostem™ into the clinic and further mature our pre-clinical portfolio.

We are now looking to establish strategic partnerships with researchers and companies interested in developing our unique stem cell-based therapies and/or utilising our ATMP manufacturing capabilities and facility.

KEY TEAM

Kåre Engkilde, MSc,PhD
CEO

- Formerly heading up Global Medical & Clinical Affairs at Agilent, and prior experience from Novo Nordisk and LEO

Johny Humaloja, MSc
CFO

- Extensive experience of financial control and management, in biotech
- Former CFO at Biogen and Boston Scientific

Jan Talts, PhD
COO

- Extensive R&D and management experience from academia, biotech industry, and health care sector
- PhD in Animal Physiology

Helle Størum, MSc
Head of BD

- 20+ years of international pharma and biotech experience within business development, corporate strategy, portfolio management and marketing

SWEDISH AMERICAN LIFE SCIENCE SUMMIT 2021

www.amniotics.com

SALSS CONTACT

Kåre Engkilde
CEO

ke@amniotics.com
+46 723 27 85 20

Amniotics AB
Medicon Village
Scheelevägen 2
223 63 Lund
Sweden

atrogi

Atrogi AB | Private Company

A POTENTIAL REVOLUTIONARY NEW THERAPEUTIC STRATEGY FOR THE TREATMENT OF TYPE 2 DIABETES

We are developing a first-in-class drug for the oral treatment of type 2 diabetes, a $159 billion global market, through a unique mode of action that targets glucose homeostasis and circumvents the insulin pathway.

Our vision is to market an insulin-independent treatment to help T2D patients live a life free from diabetes symptoms and complications.

SALSS CONTACT

Alexandra Ekman Ryding
CEO

alexandra@atrogi.com
+46 735 24 18 28

Atrogi AB
Tomtebodavägen 6
171 65 Solna
Sweden

www.atrogi.com

Type 2 diabetes is a complex disease that comes with many severe secondary disorders caused by high blood glucose levels. Atrogi was founded in 2013 based on 15+ years of ground-breaking discovery research on adrenergic signaling by Prof Tore Bengtsson at Stockholm University, which identified how to selectively stimulate blood glucose uptake in skeletal muscle. This finding is the basis of our revolutionary new therapeutic strategy for the treatment of type 2 diabetes (T2D) with minimal side effects, that will help patients to live healthier lives.

OUR PRODUCTS & SERVICES

Our development is focused around our lead compound ATR-258, which we expect to move into clinical development in 2022.

The skeletal muscle is the biggest and most important organ when it comes to lowering blood glucose levels. ATR-258 binds to the $ß_2$-AR receptor on the skeletal muscle surface, and induces an intracellular signaling pathway, which leads to translocation of glucose transporter 4 (GLUT4) to the cell surface. There, it transports glucose from the bloodstream into the muscle cell, thus lowering blood glucose back to healthy levels.

ATR-258 has been shown to have a powerful effect on glucose homeostasis. Studies in type 2 diabetic animal models have demonstrated that ATR-258 lowers blood glucose to healthy levels independent of insulin. In addition, the drug candidate enhances insulin sensitivity and lowers insulin production.

ATR-258 has potential to function as a stand-alone or a combination therapy to enhance existing insulin-pathway targeting approaches.

WHAT MAKES US UNIQUE

The first important step in the treatment of diabetes is to lower blood glucose levels. Atrogi's innovative solution has the potential to revolutionize the way in which current and future sufferers of type 2 diabetes are able to lead their lives, through a unique pathway that does not target the insulin pathway. We have strong and comprehensive IP, with clear FTO around this therapeutic strategy.

WHY YOU SHOULD MEET US

Atrogi has a potential first-in-class drug for the oral treatment of T2D with several opportunities beyond diabetes.

We are in the process of completing GLP-tox studies for our lead compound with final reports expected during upcoming months and we aim to commence clinical studies next year.

KEY TEAM

Alexandra Ekman Ryding, PhD
CEO

- Vast experience of life sciences, including VC, corporate broking and outcomes research

Prof Tore Bengtsson
Founder & CSO

- Professor of Physiology at Stockholm University
- Inventor of numerous patents and brain behind the concepts of several companies

Nodi Dehvari, PhD
Head of Biology

- 13 years in scientific research with unique knowledge of MOA

Benjamin Pelcman, PhD
Head of Chemistry &IP

- 30 years of industrial experience in drug development

Erik Rollman Waara, PhD
Head of Preclinical and Clinical Development

- 20 years in life science research
- 13 years of industrial experience in drug development

SWEDISH AMERICAN LIFE SCIENCE SUMMIT 2021

EpiEndo Pharmaceuticals

EpiEndo Pharmaceuticals ehf | Private Company

FOCUSED ON THE RESTORATION OF EPITHELIAL INTEGRITY TO TREAT INFLAMMATION

Complimenting symptomatic treatment of inflammation with a unique epithelial barrier enhancing approach that addresses underlying disease pathophysiology, with potential as an alternative to steroids.

EpiEndo's lead compound is an oral treatment that could reduce inhaler use and associated CFC emissions, while improving patient compliance.

www.epiendo.com

EpiEndo is a clinical stage pharmaceutical company with a unique focus on impairment of epithelial barriers as a common mechanism underlying the pathophysiology of many inflammatory conditions in surface-tissues such as the airway mucosa, GI tract and skin. We are trailblazing this approach with a first-in-class lead compound for the treatment of COPD. Our rationale is strongly supported by KOLs in airway disease, and a recently secured €20M capital raise both advances our clinical development to the end of Phase IIa and supports explorative R&D.

OUR PRODUCTS & SERVICES

Our lead compound, EP395, is an oral therapeutic candidate in phase I clinical development for the treatment of chronic obstructive pulmonary disease (COPD) on top of standard of care, with expansion potential into other airway diseases. COPD, the third leading cause of death worldwide, is currently untreatable, with a huge unmet need. Our primary treatment goal is to prevent or reduce inflammation by preserving and enhancing airway epithelial barrier integrity, a previously under-investigated factor in COPD pathogenesis and other airway inflammatory conditions. We also have preclinical programs in skin and GI-mucosa, targeting diseases such as ulcerative colitis and atopic dermatitis, where restorative barrier enhancement of the epithelium has likely therapeutic benefit.

WHAT MAKES US UNIQUE

Our platform approach is broadly applicable to endotypes of inflammation where barrier failure is a causal factor in different epithelia.

By targeting the epithelium, EP395 could bring both dramatic improvement to the standard of care (SOC) and potentially alleviate unwarranted use of antibiotics and overuse of inhaled corticosteroids in airway diseases.

Multi-resistant bacteria are a growing global threat and complications of intense use of corticosteroids comprise a significant concern as well as disease burden. This situation is fueled by the limited responsiveness COPD displays towards the SOC and the lack of a safe and effective therapeutic alternative.

WHY YOU SHOULD MEET US

Our vision is to transform patients' lives through the treatment of diseases caused by epithelial dysfunction. We have a strong pipeline with a fully funded clinical phase development in COPD with significant market potential as well as exciting out-licensing opportunities for our pre-clinical programs in skin and GI. We are interested to meet potential partners, investors and collaborators who would like to participate in our innovative programs.

KEY TEAM

Maria Bech, MSc
CEO

- 25 years' experience in clinical development across the pharma industry

Fridrik Gardarsson, MD
CINO & Founder

- Clinical experience in paediatrics, anaesthesia and pulmonary intensive care

Prof Dr Mike Parnham
CSO

- Former Director of Preclinical Discovery at GSK with 30+ yrs in management of discovery and preclinical development

Ginny Norris, MD
CMO

- 20+ years' experience across medical research, predominantly in respiratory therapy, with GSK and Pfizer

SALSS CONTACT

Maria Bech
CEO

maria.bech@epiendo.com
+46 73 354 20 24

EpiEndo Pharmaceuticals ehf
Eiðistorg 13
170 Seltjarnarnes
Iceland

SWEDISH AMERICAN LIFE SCIENCE SUMMIT 2021

THERAPEUTICS FOR PRODUCING FUTURES: TRANSLATING NATURE INTO NEW TREATMENTS

Building a portfolio of drugs, based on novel platforms and unique discovery strategy

www.iaterion.com

SALSS CONTACT

Isaac Cohen
President & CEO

isaac@iaterion.com
+1 510 409 2894

Iaterion, Inc.
3880 Howe Street
Oakland, CA 94611
USA

Iaterion, Inc. | Private Company

The biggest problem in biomedicine today is how to account for specificity and complexity when addressing mechanisms of disease. Diseases are neither just local nor just systemic. Our drug discovery process involves using compounds/ligands we identified through experimental studies to identify new molecular targets for drugs. Iaterion Inc., founded in 2013, provides therapeutic products for antiviral and immune modulation as well as nuclear receptor modulation based on novel platforms discovered by the founders.

OUR PRODUCTS & SERVICES

In response to COVID-19, we developed a pan-coronavirus drug that addresses the host's immune reaction that contributes most to symptoms, tissue damage and, ultimately, death. AVIM1 combines 3 compounds; two antiviral compounds: IATAV051 a RNA synthesis inhibitor, IATAV049 a proteolytic processing inhibitor of S1/S2 site and the immune modulator, IATAV052, a MyD88 inhibitor.

We also plan to develop a new class of drugs that we have discovered: nuclear receptor reprogramming (NRRP) drugs. These drugs aim to prevent the adverse effects of nuclear receptor ligand drugs, ultimately improving safety and a greater market distribution.

Our first NRRP drug is an estrogen receptor alpha (ERα) drug for the treatment of menopause. Women can benefit from long term symptom management, prevention of osteoporosis and type 2 diabetes, while diminishing the risk for breast and uterine cancers.

WHAT MAKES US UNIQUE

Our unique strategy within the biopharmaceutical industry, of using natural compounds as probes for molecular mechanism discovery, received recent recognition with the Nobel award in Physiology. We test plant and microbial derived small molecule chemicals, like the phytoanticipins, phytoalexins and plant hormone secondary metabolites to probe new molecular targets as well as to identify leads. This strategy resulted in the discovery of multiple leads, multiple targets as well as novel biological processes. We have strong affiliations and collaborations with major academic centers to advance our discoveries. Our team has broad and unique experience in developing novel therapeutics from bench to market.

WHY YOU SHOULD MEET US

Iaterion has a portfolio of drugs, based on novel platforms and unique discovery strategy that are harnessed to deliver new therapies with large and lucrative markets. We are interested to meet investors and potential licensing partners for our innovative programs.

KEY TEAM

Isaac Cohen, OMD, PhD
President and CEO

- 20+ years in drug development.
- Formerly CEO of Bionovo, Inc. (NASDAQ: BNVI)

Dale Leitman, MD, PhD
CSO

- Emeritus professor at UCSF and UC Berkeley.
- 30+ years in basic and translational research.

Carlos Milla, MD
Acting CMO

- Professor of pediatrics and pulmonary medicine, Stanford University.
- Associate Director for Translational Research at the Center for Excellence in Pulmonary Biology at Stanford

Klaus Kohl, PhD
CTO

- 30+ years in the biotech- pharmaceutical industry. Former head of quality and member of the executive team Bayer Pharmaceuticals

SWEDISH AMERICAN LIFE SCIENCE SUMMIT 2021

IMMUNOTHERAPIES USING MICROORGANISMS TO DELIVER STABLE THERAPEUTIC PROTEINS

Clinical stage gene therapy biopharmaceutical development – simple and scalable platform technology and lead projects

Ilya Pharma AB | Private Company

Ilya Pharma, founded in 2016, is a clinical stage gene therapy biopharmaceutical development company targeting unmet clinical needs in the treatment of wounds in skin and mucosa including but not limited to the gastrointestinal tract. Our innovation, the ILP-technology platform and lead candidates, uses genetically modified lactic acid bacteria to deliver stable therapeutic proteins on-site that target the function of resident immune cells to accelerate tissue regeneration and limit scaring and fibrosis development.

OUR PRODUCTS & SERVICES

The Company has significantly de-risked the ILP-candidates and projects in IP, regulatory, CMC and clinical.

ILP100-Topical is validated in a FiH trial (WHILYAS1, EudraCT No. 2019000680-24) successfully completed 2020.

A phase IIa study (WHILYAS2) in patients with diabetes and non-healing wounds, fully funded by the EIC Accelerator is approved.

In parallel, the company intends to start a phase IIb trial in treatment of incisional wounds in patients with diabetes, prediabetes and obesity in 2022.

ILP100 is also developed in an oral formulation targeting treatment of enteropathies including IBD. The project is in late pre-clinical development with an ongoing GLP-tox.

WHAT MAKES US UNIQUE

Cell- and gene therapy, biotech therapeutics, microbiome therapeutics and synthetic biology are continuing to emerge and prove clinical benefits and disrupt the traditional pharmaceutical industry where some pioneer projects have reached phase III and BLA market approvals.

In this field Ilya Pharma is differentiated by developing defined, easy to use drug candidates with low COGs and good stability, all with blockbuster potential.

WHY YOU SHOULD MEET US

The company is currently raising for the continued clinical development in phase IIs and IND enabling studies in IBD from suitable investors and potential partners with proven track record in cell- and gene therapy and therapeutics.

The company received a H2020 SME Instrument phase II grant 2018 of 3 MEUR and EIC Accelerator 2020 of 5.3 MEUR.

KEY TEAM

Evelina Vågesjö, PhD, MBA
Co-founder & CEO

- Successfully developed the concept, build a strong team and raised 20 MEUR

Ingemar Kihlström, PhD
Chairman

- Extensive experience in finance and drug development at multiple firms including Astra Zeneca and Pharmacia
- Served on the board of >30 companies

Prof Mia Phillipson, PhD
Co-founder

- Professor in Physiology at Uppsala University. Internationally recognized expert in physiology and immunology

Oskar Lund
CFO

- Deep financial management and strategic business development experience, with GE, BNP Paribas and JP Morgan

SWEDISH AMERICAN LIFE SCIENCE SUMMIT 2021

www.ilyapharma.se

SALSS CONTACT

Evelina Vågesjö
CEO

evelina.vagesjo@ilyapharma.se
+46 706 36 64 94

Ilya Pharma AB
St Goransgatan 23
753 26 Uppsala
Sweden

NEXT GENERATION END-TO-END CONTINUOUS BIOLOGICS MANUFACTURING AT COMMERCIAL SCALE

Developing new design, new equipment and new processes to produce biological drugs with the FASTEST speed to market, LOWEST manufacturing cost, and HIGHEST quality in the LARGEST segment of the pharmaceutical industry.

www.mobiusbiomedical.com

SALSS CONTACT

Vishal Jain
President & CEO

vj@mobiusbiomedical.com
+1 607 227 5080

Mobius Biomedical, Inc.
600 Suffolk St
2nd Floor Lowell
MA 01854
USA

Mobius Biomedical, Inc. | Private Company

Mobius Biomedical is addressing the increasing undersupply of clinical development and commercial manufacturing capabilities and capacities for the global biopharmaceutical industry - a $200+ billion market that is set to double over the next 10 years.

Mobius Biomedical's solution brings unprecedented efficiencies to the development and manufacturing of biopharmaceuticals (biologics) and reduces manufacturing cost by over 90% at commercial scale.

OUR PRODUCTS & SERVICES

We are developing a *de novo*, end-to-end process for continuous biological drug manufacturing to:

- Drastically reduce the manufacturing facility build-out time and costs
- Drastically reduce the manufacturing facility footprint
- Significantly reduce CAPEX and OPEX
- Increase efficiency and facility uptime
- Increase purity and yield
- Decrease waste

WHAT MAKES US UNIQUE

We are eliminating traditional protein purification techniques including centrifugation and protein A chromatography.

We have completed proof of concept to demonstrate:

- Novel approach to cell clarification
- Novel approach to Protein A affinity-based purification
- Novel approach to protein separation based on charge and pI

WHY YOU SHOULD MEET US

Today's biologics manufacturing plants take around a billion dollars and 3–5 years to deploy, and there is a worldwide shortage of manufacturing capacity.

The next generation biologics and biosimilar manufacturing plants developed using our technology will be able to complete deployment in under 18 months at a significantly lower cost versus today's state-of-the-art facilities and with a capacity that will equal the production throughput of the largest manufacturing plants in the world.

To accomplish our mission and expand our team, we are looking for investors and strategic partners.

KEY TEAM

Vishal Jain
President & CEO

- Decade of global investment banking experience in the healthcare sector with execution experience of $100+ billion of transactions

Jason Criscione, PhD
CSO

- Applied science and engineering entrepreneur with more than 10 years of experience in drug delivery and a unique expertise that covers chemistry, materials science, physics, biophysics, and biomedical engineering

Ali Ersen, PhD
VP, Engineering

- Research scientist and co-founder of a successfully exited microdisplay company where he served as its President

John Linton, PhD
VP, R&D

- Seasoned R&D leader and product development expert with 25+ years experience

SWEDISH AMERICAN LIFE SCIENCE SUMMIT 2021

SAGA DIAGNOSTICS
FOR PRECISION CANCER MEDICINE

SAGA Diagnostics AB | Private Company

ULTRASENSITIVE CANCER DIAGNOSTICS AND MONITORING

Our mission is to improve personalized cancer genomics and disease monitoring by introducing the most ultrasensitive molecular genetic testing of minimally-invasive "liquid biopsies" such as blood samples into routine cancer care worldwide.

SAGA Diagnostics is a personalized cancer genomics and disease monitoring company that offers molecular genetic testing of tissue biopsies and non-invasive liquid biopsies such as blood samples. We use digital PCR and next-generation sequencing to offer ultrasensitive monitoring of circulating tumor DNA (ctDNA), a powerful cancer biomarker which we use to stratify patients, monitor response to treatment, and help direct therapeutic choices. SAGA provides testing products and services to leading pharma, academia, and healthcare laboratories worldwide.

OUR PRODUCTS & SERVICES

SAGAsafe® uses digital PCR to detect and quantify mutations with unique ultrasensitivity to 0.001% MAF (Mutant Allele Frequency), which is approximately 100-fold improved compared to competing methods. We offer CE-IVD and RUO kits and services.

SAGAsign® is a unique hybrid method which is ideal for monitoring of response to therapy, minimal residual disease (MRD), and early detection of recurrences. Due to the ultrasensitivity of the method, we have been able to detect cancer recurrences up to 3 years prior to traditional methods.

SAGAseq®, to be launched Q4'21, marries enhanced sequencing library preparation together with AI/machine learning bioinformatics to reduce sequencing noise and increase true-positive signal.

WHAT MAKES US UNIQUE

SAGA's proprietary tests are rapid, cost-effective, and the most ultrasensitive – we detect what other methods cannot. SAGA's kits and services can help patients, oncologists, and drug developers detect mutations, stratify patient groups, and monitor treatment response, residual disease, and disease recurrence with an industry-leading lower limit of detection down to 0.001%.

WHY YOU SHOULD MEET US

The cancer "liquid biopsy" sector is rapidly developing field that is set to revolutionize the management of cancer patients. We have recently raised SEK 106 million (€10.5 million) Series A2 and have ambitious growth plans.

We are looking to extend SAGA's range of CE-marked SAGAsafe® assays, accelerate the commercialization of SAGAsign® in minimal residual disease monitoring, launch the SAGAseq® platform, and establish a USA CLIA laboratory capability to support global clinical trials.

KEY TEAM

Peter Collins
CEO

- 30+ years of experience in pharma, diagnostics, and cancer liquid biopsy
- Formerly CBO of Invata ($415 million exit 2021), VP Biopharma BD at Guardant Health, CBO of Yourgene, and VP Head of Diagnostics at GSK

Lao Saal, MD,PhD
COO & Co-Founder

- Over 20 years of experience in cancer genomics research, and 10 years in executive roles including 6 as founding CEO of SAGA
- Spinout from Lund University, Sweden, over €15 million raised, growth to 18 FTE
- 10,000+ citations, publications in Science, Nature Genetics, and PNAS

SALSS CONTACT

Peter Collins
CEO

info@sagadiagnostics.com
+46 733 01 72 42

SAGA Diagnostics AB
Scheelevägen 2, MV 406
223 81 Lund
Sweden

sagadiagnostics.com

SWEDISH AMERICAN LIFE SCIENCE SUMMIT 2021

SIGRID THERAPEUTICS

Sigrid Therapeutics AB | Private Company

TRANSFORMING THE WAY WE PREVENT AND TREAT CHRONIC LIFESTYLE DISEASES

Every year 70% of all deaths globally are attributed to lifestyle diseases such as obesity, type 2 diabetes and heart disease.

Sigrid's breakthrough biomaterial acts in the gut, aiming to prevent lifestyle disease by improving the blood sugar levels of people at risk of developing diabetes.



Sigrid Therapeutics is a privately-held clinical-stage health tech company pioneering a new class of patented and sustainable biomaterials to prevent and treat type 2 diabetes and its related diseases. Sigrid's first product under development, SiPore15™, is a naturally sourced, carefully engineered silica mineral consumed orally to reduce blood sugar, LDL cholesterol and body weight. The product is classified as a medical device in Europe and as a food supplement worldwide. SiPore15™ is set for commercialization in 2022.

OUR PRODUCTS & SERVICES

Sigrid's patented SiPore™ platform technology is uniquely positioned to combat metabolic diseases through its safety, efficacy and sustainability.

The clinically-proven platform technology consists of engineered silica with a tailored surface chemistry, porosity and architecture, enabling them to entrap digestive enzymes inside the gut. Products based on SiPore™ technology are consumer friendly; the powder can be mixed in a glass of water or sprinkled over the food. As a tasteless and odourless white powder, it has ideal characteristics to be formulated into many different products -- and therefore broad licensing potential.

Our first product in development, SiPore15™ is a breakthrough medical device for the safe reduction of blood sugar levels in people at risk of developing diabetes, prediabetics, and newly diagnosed type 2 diabetics. Upon its approval, SiPore15™ will be the first treatment available for prediabetes, with the potential to prevent type 2 diabetes.

WHAT MAKES US UNIQUE

- Superior safety: SiPore™ technology works locally in the gut and is not absorbed.
- Sustainability: silica enjoys GRAS status (generally recognized as safe by the FDA) and is as gentle to the environment as to the human body.
- Efficacy: Clinical trials with SiPore15™ show it is more effective than Metformin (type 2 diabetes drug) in reducing blood sugar levels in prediabetics.

WHY YOU SHOULD MEET US

Sigrid is at a very exciting junction today; on the verge of commercial breakthrough. We seek partners for marketing and distribution of SiPore15™ globally. The Company has a pipeline of products combating different metabolic disorders and diseases and we are always prepared to meet investors to advance our product pipeline.

KEY TEAM

Ulf Wiinberg
Executive Chairman

- Pharma industry professional with 30+ years of experience
- Former President of global consumer health care and President, Europe at Wyeth, former CEO of Lundbeck

Sana Alajmovic
CEO & Co-Founder

- 11+ years of diverse experience in business development and senior management within the life science industry

Prof. Tore Bengtsson
CSO & Co-Founder

- Specialized in physiology and molecular biosciences at Stockholm University
- Successful startups, include Atrogi AB, Glucox Biotechnology AB and Symcel AB.

Eric Johnston, MSc, PhD
CTO

- Specialized in the design and production of synthetic mesoporous silica

SALSS CONTACT

Sana Alajmovic
CEO

sana@sigridthx.com
+46 723 89 33 96

Sigrid Therapeutics
Fogdevreten 2
171 65 Solna
Sweden

SWEDISH AMERICAN LIFE SCIENCE SUMMIT 2021

BUILDING THE WORLD'S BEST ONE-STOP-SHOP FOR ADVANCED ELECTRON MICROSCOPY SERVICES

- Vironova is looking to build a dominant franchise in a booming multi-$BN market growing by 36% p.a. to $27bn by 2025, as demand for nanoparticle analysis and expertise increases driven by new and continuously changing regulatory QC requirements for gene therapy and the vaccine industry.

Vironova BioAnalytics

Vironova BioAnalytics AB | Private Company

Vironova BioAnalytics is a wholy-owned subsidiary of Vironova, focused on building the world's best one-stop solution for advanced electron microscopy service (EM service), as well as performing viral clearance studies for biological drugs. We address key customer needs for GMP compliance and simplified testing processes. As the world's only GMP-certified EM player, Vironova BioAnalytics is the preferred partner for life science companies, setting a new gold standard for safe and effective therapy development.

OUR PRODUCTS & SERVICES

EM Service: We specialize in nanoparticle analysis with a specific focus on the characterization of components that are used for vaccines and gene therapies. We have full GMP-certified analysis which can effectively address the safety, efficacy, and stability of products. We provide useful morphological information that is translated into quantitative and qualitative data that aids in faster and informed decisions.

Biosafety Service: Viral clearance studies in GLP-certified laboratories, serving early R&D to on-market. We also offer literature-based viral risk assessment by experts with extensive scientific and regulatory experience.

WHAT MAKES US UNIQUE

- We are the only GMP-certified EM lab in the world which utilizes the same method across the full lifecycle, de-risked with FDA/EMA approval.
- We are already a trusted service provider to 200+ established customers globally.
- World-class expertise with experienced management and professional team of >120, including 52% PhDs and microscopists with 100+ years of EM experience.
- Secured position with comprehensive Intellectual property portfolio.

WHY YOU SHOULD MEET US

Vironova BioAnalytics' customers gain value from our best-in-class quality testing, independent of the development phase step across the full lifecycle. Meeting regulatory requirements leverages up to 3 years of time-to-market reduction through early, granular testing.

Unicorn potential: We have demonstrated significant growth since the commercialization of the company (50% p.a. over the past 5 years) and have a growth strategy in place to reach unicorn status by 2025.

KEY TEAM

Mohammed Homman
CEO

- Founder of Vironova AB and Vironova Medical AB and has spent 10+ years researching at KI
- MSc in Chemistry and BSc in Biology from Uppsala University

Josefina Nilsson, PhD
Director of EM Services

- PhD in Biophysics and Structural Biology from Karolinska Institutet.
- Expertise in structural analysis of viruses and nanoparticles, electron microscopy with 15+ years experience

Rickard Nordström
Senior Manager EM Services

- Molecular biologist, electron microscopist with over 10 years lab and EM industrial application experiencerience

SALSS CONTACT

Josefina Nilsson
Direct of EM Services

josefina.nilsson@vironova.com
+46 76 109 01 91

Vironova BioAnalytics
Gävlegatan 22
113 30 Stockholm
Sweden

www.vironova.com

SWEDISH AMERICAN LIFE SCIENCE SUMMIT 2021

produced for SALSS by

Strategic Consulting | Capital Sourcing | Investor Communications

SWEDISH AMERICAN LIFE SCIENCE SUMMIT 2021